期刊
CANCERS
卷 8, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/cancers8060057
关键词
renal cell carcinoma; Wnt signaling pathway; therapeutic target; development
类别
资金
- Academy of Finland [206038, 121647]
- Centre of Excellence from the Academy of Finland [251314]
- FiDiPro [S.Q. 263246]
- Sigrid Juselius Foundation, the European Community's Seventh Framework Programme [FP7
- FP7-HEALTH-F5-2012-INNOVATION-1 EURenOmics [305608]
- Cancer Society of Finland
- Academy of Finland (AKA) [121647, 206038] Funding Source: Academy of Finland (AKA)
Renal cell carcinoma (RCC) accounts for 90% of all kidney cancers. Due to poor diagnosis, high resistance to the systemic therapies and the fact that most RCC cases occur sporadically, current research switched its focus on studying the molecular mechanisms underlying RCC. The aim is the discovery of new effective and less toxic anti-cancer drugs and novel diagnostic markers. Besides the PI3K/Akt/mTOR, HGF/Met and VHL/hypoxia cellular signaling pathways, the involvement of the Wnt/beta-catenin pathway in RCC is commonly studied. Wnt signaling and its targeted genes are known to actively participate in different biological processes during embryonic development and renal cancer. Recently, studies have shown that targeting this pathway by alternating/inhibiting its intracellular signal transduction can reduce cancer cells viability and inhibit their growth. The targets and drugs identified show promising potential to serve as novel RCC therapeutics and prognostic markers. This review aims to summarize the current status quo regarding recent research on RCC focusing on the involvement of the Wnt/beta-catenin pathway and how its understanding could facilitate the identification of potential therapeutic targets, new drugs and diagnostic biomarkers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据